{"transactions":[{"id":976170,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":71987,"kind":"person","name":"Gangloff Scott A.","position":1,"cik":"0001663253","reported_name":"Gangloff Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:11:46.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":204616,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":19.62,"expiration_date":"2034-04-29","underlying":"Common Stock","underlying_shares":204616},"source":{"system":"sec-edgar","filing":"0001193125-25-312111","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312111/ownership.xml","form_type":"4"}},{"id":976169,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":71987,"kind":"person","name":"Gangloff Scott A.","position":1,"cik":"0001663253","reported_name":"Gangloff Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:11:46.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":73700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":29.23,"expiration_date":"2034-12-16","underlying":"Common Stock","underlying_shares":73700},"source":{"system":"sec-edgar","filing":"0001193125-25-312111","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312111/ownership.xml","form_type":"4"}},{"id":976168,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":71987,"kind":"person","name":"Gangloff Scott A.","position":1,"cik":"0001663253","reported_name":"Gangloff Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:11:46.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17784,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":19.62,"expiration_date":"2034-04-29","underlying":"Common Stock","underlying_shares":17784},"source":{"system":"sec-edgar","filing":"0001193125-25-312111","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312111/ownership.xml","form_type":"4"}},{"id":976167,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":71987,"kind":"person","name":"Gangloff Scott A.","position":1,"cik":"0001663253","reported_name":"Gangloff Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2025-12-09T10:11:46.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":21263,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units (\"Company RSUs\") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU (a \"Company RSU\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-312111","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312111/ownership.xml","form_type":"4"}},{"id":976166,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":71987,"kind":"person","name":"Gangloff Scott A.","position":1,"cik":"0001663253","reported_name":"Gangloff Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2025-12-09T10:11:46.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5088,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NN Invest Sub, Inc (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025 (such date and time, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer (\"Company Common Stock\") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the \"Closing Consideration\") and (ii) one contractual contingent value right (a \"CVR\") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NN Invest Sub, Inc (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025 (such date and time, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer (\"Company Common Stock\") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the \"Closing Consideration\") and (ii) one contractual contingent value right (a \"CVR\") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-312111","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312111/ownership.xml","form_type":"4"}},{"id":1061923,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":71987,"kind":"person","name":"Gangloff Scott A.","position":1,"cik":"0001663253","reported_name":"Gangloff Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock option (Right to Buy)","published_at":"2025-08-19T21:32:05.000Z","date":"2025-08-15","kind":"exercise","planned":false,"acquired":false,"shares":2600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five (25) percent of the shares subject to this option shall vest and become exercisable on April 29, 2025, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":17784,"derivative":{"exercise_price":19.62,"expiration_date":"2034-04-28","underlying":"Common Stock","underlying_shares":20384},"source":{"system":"sec-edgar","filing":"0000950170-25-110352","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025110352/ownership.xml","form_type":"4"}},{"id":1061922,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":71987,"kind":"person","name":"Gangloff Scott A.","position":1,"cik":"0001663253","reported_name":"Gangloff Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2025-08-19T21:32:05.000Z","date":"2025-08-15","kind":"exercise","planned":false,"acquired":true,"shares":2600,"price":19.62,"value":51012.0,"ownership":{"direct":true},"balance_after":26351,"source":{"system":"sec-edgar","filing":"0000950170-25-110352","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025110352/ownership.xml","form_type":"4"}},{"id":1095275,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":71987,"kind":"person","name":"Gangloff Scott A.","position":1,"cik":"0001663253","reported_name":"Gangloff Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2025-07-02T18:00:11.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":299,"price":23.868,"value":7136.532,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. Gangloff is voluntarily reporting the acquisition of these shares on June 30, 2025 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the provisions of the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan, these shares were purchased at 85% of the closing price of the Issuer's common stock on January 2, 2025."}],"balance_after":23751,"source":{"system":"sec-edgar","filing":"0000950170-25-093317","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025093317/ownership.xml","form_type":"4"}},{"id":1105059,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":71987,"kind":"person","name":"Gangloff Scott A.","position":1,"cik":"0001663253","reported_name":"Gangloff Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2025-06-20T21:08:53.000Z","date":"2025-06-18","kind":"sale","planned":false,"acquired":false,"shares":848,"price":54.84,"value":46504.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.73 to $54.84, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":23452,"source":{"system":"sec-edgar","filing":"0000950170-25-088640","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025088640/ownership.xml","form_type":"4"}},{"id":1326781,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":71987,"kind":"person","name":"Gangloff Scott A.","position":1,"cik":"0001663253","reported_name":"Gangloff Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-18T20:56:09.000Z","date":"2024-12-16","kind":"grant","planned":false,"acquired":true,"shares":73700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing from December 16, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":73700,"derivative":{"exercise_price":29.23,"expiration_date":"2034-12-15","underlying":"Common Stock","underlying_shares":73700},"source":{"system":"sec-edgar","filing":"0000950170-24-138138","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024138138/ownership.xml","form_type":"4"}},{"id":1326780,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":71987,"kind":"person","name":"Gangloff Scott A.","position":1,"cik":"0001663253","reported_name":"Gangloff Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2024-12-18T20:56:09.000Z","date":"2024-12-16","kind":"grant","planned":false,"acquired":true,"shares":24300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in eight (8) equal semi-annual installments, commencing from December 16, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":24300,"source":{"system":"sec-edgar","filing":"0000950170-24-138138","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024138138/ownership.xml","form_type":"4"}},{"id":1532033,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":71987,"kind":"person","name":"Gangloff Scott A.","position":1,"cik":"0001663253","reported_name":"Gangloff Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-01T19:36:34.000Z","date":"2024-04-29","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five (25) percent of the shares subject to this option shall vest and become exercisable on April 29, 2025, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":225000,"derivative":{"exercise_price":19.62,"expiration_date":"2034-04-28","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000950170-24-051488","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024051488/ownership.xml","form_type":"4"}},{"id":4512998,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":71987,"kind":"person","name":"Gangloff Scott A.","position":1,"cik":"0001663253","reported_name":"Gangloff Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Development & Mfrg"}}],"security":"Common Stock","published_at":"2016-12-22T23:01:49.000Z","date":"2016-12-21","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This security represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares underlying this restricted stock unit award vests in two equal installments on each of December 21, 2017 and December 21, 2018, in each case subject to the Reporting Person's continuous service to the Issuer through each such date. In addition, 100% of the shares underlying the restricted stock unit award will satisfy the time-based vesting restrictions upon the occurrence of a change of control, subject to continued service through such event."}],"balance_after":118573,"source":{"system":"sec-edgar","filing":"0001209191-16-156579","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000120919116156579/doc4.xml","form_type":"4"}},{"id":4557109,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":71987,"kind":"person","name":"Gangloff Scott A.","position":1,"cik":"0001663253","reported_name":"Gangloff Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Development & Mfrg"}}],"security":"Common Stock","published_at":"2016-11-14T23:36:04.000Z","date":"2016-11-11","kind":"sale","acquired":false,"shares":37369,"price":3.75,"value":140133.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on November 9, 2016. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person."}],"balance_after":78573,"source":{"system":"sec-edgar","filing":"0001214659-16-014641","document":"marketforms-36767.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000121465916014641/marketforms-36767.xml","form_type":"4"}},{"id":4557108,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":71987,"kind":"person","name":"Gangloff Scott A.","position":1,"cik":"0001663253","reported_name":"Gangloff Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Development & Mfrg"}}],"security":"Common Stock","published_at":"2016-11-14T23:36:04.000Z","date":"2016-11-09","kind":"exercise","acquired":true,"shares":115942,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the right to receive, at settlement, one (1) share of the Issuer's common stock."}],"balance_after":115942,"source":{"system":"sec-edgar","filing":"0001214659-16-014641","document":"marketforms-36767.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000121465916014641/marketforms-36767.xml","form_type":"4"}},{"id":4557107,"issuer":{"id":608,"kind":"organization","name":"Outlook Therapeutics, Inc.","symbol":"OTLK"},"owners":[{"id":71987,"kind":"person","name":"Gangloff Scott A.","position":1,"cik":"0001663253","reported_name":"Gangloff Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Development & Mfrg"}}],"security":"Restricted Stock Units","published_at":"2016-11-14T23:36:04.000Z","date":"2016-11-09","kind":"exercise","acquired":false,"shares":115942,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's 2015 Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the right to receive, at settlement, one (1) share of the Issuer's common stock."},{"field":"shares","element":"transactionShares","label":"F3","text":"The RSUs vest upon the first to occur of (x) a change of control as defined in the award agreement and (y) the expiration of the 6 month lock-up period following the Issuer's initial public offering, in each case subject to continued service through such event."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001214659-16-014641","document":"marketforms-36767.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649989/000121465916014641/marketforms-36767.xml","form_type":"4"}}]}